Antithrombotic therapy and nonvariceal upper gastrointestinal bleeding

Česká verzia

Authors: Veronika Belanová ¹; Martin Gřiva ²
Authors place of work: Oddělení intenzivní péče operačních oborů Krajské nemocnice T. Bati, a. s., Zlín, vedoucí pracoviště prim. MUDr. Anna Šobáňová ¹; Kardiocentrum pro dospělé Interní kliniky Krajské nemocnice T. Bati, a. s., Zlín, vedoucí pracoviště prim. MUDr. Jiří Latta ²
Published in the journal: Vnitř Lék 2015; 61(12): 1016-1022
Category: Original Contributions

Summary

Background:
The incidence of acute upper gastrointestinal bleeding is about 85–108/100,000 inhabitants per year, nonvariceal bleeding accounts for 80–90 %. Antiplatelet and anticoagulation treatment are the significant risk factors for upper gastrointestinal bleeding.

Objectives:
To evaluate the occurrence of upper gastrointestinal bleeding in the general community of patients in a county hospital. And to compare the role played by antiplatelet and anticoagulation drugs and other risk medication.

Design and methods:
Retrospective analysis of patients over 18 years of age who underwent endoscopy for acute upper gastrointestinal bleeding or anaemia (haemoglobin < 100 g/l) with proved source of blood losses in upper gastrointestinal tract during a hospital stay in 2013 (from January to June).

Results:
We included 111 patients of average age 69 ± 15 years, men 60 %. Nonvariceal bleeding accounted for 90 % of the cases. None of the patients with variceal bleeding (10 % of patients) took antiplatelet or anticoagulation therapy. There were 100 patients with nonvariceal bleeding of average age 70 ± 15, 61 % men. With the symptoms of acute bleeding (hematemesis, melena) presented in 73 % of patients. The most frequent cause of bleeding was gastric and duodenal ulcer (54 %). 32 % of patients with nonvariceal bleeding had antiplatelets, 19 % anticoagulants and 10 % used nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors or corticosteroids. 30-days mortality of patients with nonvariceal bleeding was 11 %, annual mortality was 23 %. There was no significant difference in mortality, blood transfusion requirements or surgical intervention between the patients with antithrombotic agents and without them. 25 % of patients (8 patients) using acetylsalicylic acid did not fulfil the indication for this treatment.

Conclusion:
Among the patients examined by endoscopy for symptomatic nonvariceal bleeding and/or anaemia (haemoglobin < 100 g/l) significantly higher portions of patients are taking antiplatelet rather than anticoagulation therapy. This may be caused by greater use of these drugs in the population, but on the other hand it may reflect an association with greater risk of gastrointestinal bleeding. With regard to that, it is alarming, that there still exists a nonnegligible percentage of patients taking acetylsalicylic acid even though they do not meet the indication for the prescription according to the guidelines.

Key words:
antiplatelet therapy and anticoagulation – upper gastrointestinal bleeding

Zdroje

1. Crooks C, West J, Card T. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61(4): 514–520.

2. Paspatis GA, Konstantinidis K, Chalkiadakis I et al. Changing trends in acute upper gastrointestinal bleeding in Crete, Greece: a population-based study. Eur J Gastroneterol Hepatol 2012; 24(1): 102–103.

3. Loperfido S, Baldo V, Piovesana E at al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest endosc 2009; 70(2): 212–224.

4. Theocharis GJ, Thomopoulos KC, Sakellaropoulos G et al. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol 2008; 42(2): 128–133.

5. Palmer K. Acute upper gastrointestinal heamorrhage. Br Med Bull 2007; 83: 307–324.

6. Van Leerdam ME, Vreeburg EM, Rauws EAJ et al. Acute Upper GI Bleeding: Did Anything Change?, Time Trend Analysis of Incidence and Outcome of Acute Upper GI Bleeding Between 1993/1994 and 2000. Am J Gastroenterol 2003; 98(7): 1494–1499.

7. Esrailian E, Gralenk IM. Nonvariceal Upper Gastrointestinal Bleeding: Epidemiology and Diagnosis. Gastroenterol Clin North Am 2005; 34(4): 589–605.

8. Tariq SH, Mekhijan G. Gastrointestinal Bleeding in Older Adults. Clin Geriatr Med 2007; 23(4): 769–784.

9. Hearnshaw SA, Logan RF, Lowe D et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60(10): 1327–1335.

10. Di Fiore F, Lecleire S, Merle V et al. Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and prectices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 2005; 17(6): 641–647.

11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333(7571): 726.

12. Delaney JA, Opatrny L, Brophy JM et al. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177(4): 347–351.

13. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731–1738.

14. Hreinsson JP, Kalaitzakis E, Gudmundsson S et al. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol 2013; 48(4): 439–447.

15. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27(1): 31–40.

16. Dall M, Schaffalitzky de Muckadell OB, Lassen AT et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7(12): 1314–1321.

17. Åhsberg K, Höglund P, Kim WH et al. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010; 45(12): 1404–1415.

18. Thomopoulos KC, Vagenas KA, Vagianos CE et al. Changes in aetiology and clinical outcome of acute upper gastrointestinal bleeding during the last 15years. Eur J Gastroneterol Hepatol 2004; 16(2): 177–182.

19. Pisters R, Lane DA, Nieuwlaat H et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093–1100.

20. Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143(1): 179–184.

21. Caldeira D, Costa J, Fernandes RM et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014; 40(3): 277–284.

22. Lip GYH, Frison L, Halperin JL et al. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation. J Am Coll Cardiol 2011; 57(2): 173–180.

23. Morales-Uribe CH, Sierra-Sierra S, Hernándéz-Hernández AM et al. Upper gastrointestinal bleeding: risk factors for mortality in two urban centers in Latin America. Rev Esp Enferm Dig 2001; 103(1): 20–24.

24. Barkun A, Sabbah S, Enns R et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhinition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99(7): 1238–1246.

25. Hnízdil L, Piskač P, Dvořák M et al. Akutní endoskopické řešení krvácení do horní části gastrointestinálního traktu: zkušenosti jednadvaceti let. Prakt Lék 2011; 91(7): 404–408.

26. Bureš J, Kopáčová M, Škodová Fendrichová M et al. Epidemiologie Helicobacter pylori. Vnitř Lék 2011; 57(12): 993–999.

27. Bureš J, Kopáčová M, Koupil I et al. Significant decrease in prevalence of Helicobacter pylori in the Czech Republic. World J Gastroenterol 2012; 18(32): 4412–4418.

28. Kopacova M, Koupil I, Seifert B et al. Blood pressure and stature in Helicobacter pylori positive and negative persons. World J Gastroenterol 2014; 20(19): 5625–5631.

29. Wikman-Jorgensen P, Lopéz-Calleja E, Safont-Gasó P et al. Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev Esp Enferm Dig 2011; 103(7): 360–365.

30. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635–1701. Erratum in Eur Heart J 2012; 33(17):2126.

31. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719–2747. Erratum in Eur Heart J 2013; 34(10): 790. Eur Heart J 2013; 34(36): 2850–2851.

32. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159–2219.

33. Penka M, Schwarz J, Campr V et al. Shrnutí doporučení České pracovní skupiny pro Ph-negativní myeloproliferativní onemocnění (CZEMP) České hematologické společnosti ČLS JEP pro diagnózu a terapii BCR/ABL-negativních myeloproliferací. Vnitř Lék 2012; 58(2): 163–168.

34. Lukáš M, Špičák J, Keil R. Doporučení České gastroenterologické společnosti pro podávání antiagregační terapie kyselinou acetylsalicylovou. Gastroent Hepatol 2013; 67(2): 90–94.

35. Bureš J, Dítě P, Fixa B et al. Infekce Helicobacter pylori. Doporučený postup České gastroenterologické společnosti ČSL JEP pro dospělé. Gastroent Hepatol 2013; XX–XX (Guidelines): 1–5.Dostupné z WWW: http://www.cgs-cls.cz/wp-content/uploads/2015/04/guidelines-infekce-helicobacter-pylori.pdf.

36. Konečný M, Ehrmann J, Procházka V et al. Naše zkušenosti s novou organizací péče o nemocné s akutním krvácením do horní části trávicího traktu. Vnitř Lék 2005; 51(1): 36–40.